Skip to main content
Clinical Trials/NCT06003608
NCT06003608
Active, Not Recruiting
N/A

Observational, Cross-sectional Clinical Study in Parkinson's Disease (PD) Patients and Healthy Controls (HC) to Identify PD Specific Microbial and Metabolic Fingerprints in Small Intestinal (SI) Fluid and Blood

Nimble Science Ltd.1 site in 1 country100 target enrollmentFebruary 19, 2024

Overview

Phase
N/A
Intervention
Fluid biopsy capsule
Conditions
Parkinson Disease
Sponsor
Nimble Science Ltd.
Enrollment
100
Locations
1
Primary Endpoint
Difference in microbiome profile of small intestine samples between groups
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally and recovered together with the stools (home recovery) together with blood sampling (during the onsite visit).

Detailed Description

Participants will be swallowing two SIMBA capsules which allows for minimally-invasive sampling of the microbiome and metabolome deep in the small intestine. Researchers will use the capsule samples to determine the small intestinal microbiome and metabolomic signatures in luminal fluid samples from the small bowel in Parkinson Disease (PD) patients compared to healthy controls (HC).

Registry
clinicaltrials.gov
Start Date
February 19, 2024
End Date
February 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Healthy control (HC)

25 neurotypical controls, age-matched to the Parkinson's disease group

Intervention: Fluid biopsy capsule

Parkinson's disease (PD)

75 Parkinson's disease patients

Intervention: Fluid biopsy capsule

Parkinson's disease (PD)

75 Parkinson's disease patients

Intervention: Levodopa-Carbidopa Immediate Release

Outcomes

Primary Outcomes

Difference in microbiome profile of small intestine samples between groups

Time Frame: Baseline

Functional dysbiosis profile of the small intestinal microbiota of Parkinson's Disease patients compared to age-matched neurotypical controls, as determined by whole metagenome shotgun sequencing based profiling

Secondary Outcomes

  • Difference in blood metabolome composition between groups(Baseline)
  • Correlation between the observed small intestine microbiome profile and blood metabolome composition, including, in PD subjects, levodopa pharmacodynamics(Baseline)

Study Sites (1)

Loading locations...

Similar Trials